• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
PVP-K30-----pharma excipients(CAS No.9003-39-8)
Tobramycin
Povidone iodine 20% powder
Povidone iodine 10% powder
SULBACTAM SODIUM STERILE
Food Additives Bulk Sucralose Neotame Advantame Powder

Novartis appoints new CEO for controversial Korean unit

biospectrumasiaAugust 24, 2018

Tag: Novartis , CEO , Korean unit

Novartis has appointed the former chief of its Asia Pacific operations, Joshi Venugopal, as interim CEO of its Korea business replacing another interim CEO, Klaus Ribbe, who plans to retire next month.

The Novartis Korea unit has been rocked by allegations of a kickback scheme to doctors aimed at driving prescriptions. Former CEO Moon Hak-sun took a leave of absence in 2016 and was indicted a short time later along with five other senior executives.

-----------------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.

 

Previous:Gritstone Oncology files for $80M IPO

Next:FDA Takes Action to Address Epipen Shortages

Related News

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China

PharmaSourcesSeptember 19, 2024

InnoCare Pharma announced today the approval of the Investigational New Drug (IND) to conduct the clinical trial of B-cell lymphoma-2 (BCL2) inhibitor ICP-248 in combination with azacitidine for acute myeloid leukemia (AML) in China.

Cordlife Unveils Enhanced Processing and Storage Facility in Singapore; Strengthens Processes as It Resumes Collection of Cord Blood Units in a Controlled Manner

PharmaSourcesSeptember 18, 2024

Latest Data of InnoCare’s Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2024

PharmaSourcesSeptember 14, 2024

Novartis appoints new CEO for controversial Korean unit | Pharmasources.com

Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study

Biotech NewswireAugust 28, 2024

Currax Pharmaceuticals LLC announced the results of a Cardiovascular Health Outcomes Analysis.The results showed there is no evidence of excess cardiovascular risk.

You may like
More>>

Ceotaxime Sodium for Injection

Ceotaxime Sodium for Injection
Diatomaceous earth

Diatomaceous earth
Diatomaceous earth

Diatomaceous earth
Diatomaceous earth

Diatomaceous earth
Calceolarioside B

Calceolarioside B
Paeoniflorin Paeonia Lactiflora 50% Paeoniflorin-Extract Plant Herbaceous Powder White Peony Root Ex

Paeoniflorin Paeonia Lactiflora 50% Paeoniflorin-Extract Plant Herbaceous Powder White Peony Root Ex
PHENOXYMETHYL PENICILLIN POTASSIUM

PHENOXYMETHYL PENICILLIN POTASSIUM
LINCOMYCIN HCL

LINCOMYCIN HCL
GENTAMYCIN SULPHATE macrolides

GENTAMYCIN SULPHATE macrolides
CEFALEXINE cephalosporins

CEFALEXINE cephalosporins

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service